Abstract 16P
Background
This study aimed to assess preferences of patients and healthcare practitioners (HCPs) regarding treatment attributes for early-stage triple-negative breast cancer (TNBC) in the Asia-Pacific region.
Methods
A discrete choice experiment (DCE) was conducted in Australia, Korea, Philippines, Japan, and Taiwan, with 115 patients who self-reported a diagnosis of early-stage TNBC and 86 HCPs. Key attributes relevant to TNBC treatment decision-making were verified through qualitative interviews with clinical experts. A D-efficient fractional-factorial design was employed to create 15 online choice sets with seven key attributes: disease-free/event-free survival (DFS/EFS), pathological complete response (pCR), chance of undergoing breast conserving surgery after receiving anticancer treatment, febrile neutropenia, peripheral sensory neuropathy, diarrhea, and irreversible endocrine-related adverse events (AEs) requiring lifelong medication. A mixed logit model was used to estimate preference weights for attribute levels, which were then used to compute the relative importance score (RIS) for each attribute.
Results
Median age of patients were 44.0 (interquartile range 38.0-56.5) years. 68% of patients were married, 77% had children, 40% employed full-time and 70% had a college degree. 46% of patients were diagnosed below the age of 40. Among the HCPs, 58% were medical oncologists and the remaining breast or general surgeons. PCR, DFS/EFS, and peripheral sensory neuropathy were the three most important attributes in both HCP and patient groups. pCR had the highest weighted preference among patients and HCPs (RIS, 28.46 and 32.86, respectively). In general, patients assigned greater weight to safety attributes compared to HCPs, while HCPs assigned more weight to efficacy attributes than patients. Surgeons assigned more weight for irreversible endocrine-related AEs than medical oncologists (RIS, 14.4 vs. 5.4).
Conclusions
Overall, patients and HCP preferences were aligned in ranking for efficacy and safety attributes tested. Differences in preferences within the regions were notable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA Solutions Asia Pte. Ltd.
Funding
MSD International GmbH, Singapore Branch.
Disclosure
J. Lai, Y. Antill, K.H. Jung, C. Shimizu, M.L. Abesamis Tiambeng: Financial Interests, Personal, Advisory Board: MSD. E.M. Tan, S. Qu: Financial Interests, Personal, Full or part-time Employment, IQVIA was commissioned to carry out this study.: IQVIA Asia Pacific. C. Spiteri, S.Y. Ihm, D. Hsu: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract